A Phase 1b|[sol]|2 trial of mapatumumab in patients with relapsed|[sol]|refractory non-Hodgkin's lymphoma

A Younes; J M Vose; A D Zelenetz; M R Smith; H A Burris; S M Ansell; J Klein; W Halpern; R Miceli; E Kumm; N L Fox; M S Czuczman

首页> 外文期刊>British Journal of Cancer >A Phase 1b|[sol]|2 trial of mapatumumab in patients with relapsed|[sol]|refractory non-Hodgkin's lymphoma

【24h】

A Phase 1b|[sol]|2 trial of mapatumumab in patients with relapsed|[sol]|refractory non-Hodgkin's lymphoma

机译：Mapatumumab在复发[| sol] |难治性非霍奇金淋巴瘤患者中的1b | [sol] | 2期临床试验

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with relapsed non-Hodgkin's lymphoma (NHL).

机译：背景：我们进行了一项多中心1b / 2期临床试验，以评估Mapatumumab（一种针对肿瘤坏死因子相关凋亡诱导配体受体1（TRAIL-R1）的全人类激动性单克隆抗体）在非复发性非小细胞肺癌患者中的安全性和有效性。霍奇金淋巴瘤（NHL）。

著录项

来源
《British Journal of Cancer》 |2010年第12期|共5页
作者
A Younes; J M Vose; A D Zelenetz; M R Smith; H A Burris; S M Ansell; J Klein; W Halpern; R Miceli; E Kumm; N L Fox; M S Czuczman;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma [J] . Maddocks Kami, Christian Beth, Jaglowski Samantha, Blood: The Journal of the American Society of Hematology . 2015,第2期

机译：一项未经治疗和复发/难治性非霍奇金淋巴瘤患者的利妥昔单抗，苯达莫司汀和依鲁替尼的1 / 1b期研究
2. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. [J] . Srivastava S, Jones D, Wood LL, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2011,第7期

机译：高剂量氯法拉滨，依托泊苷，环磷酰胺和自体外周血干细胞移植在原发性难治性和复发性及难治性非霍奇金淋巴瘤患者中进行的I期试验。
3. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). [J] . Zwick C, Birkmann J, Peter N, Annals of hematology . 2008,第9期

机译：推注和依托泊苷的等效毒性：德国高级别非霍奇金淋巴瘤研究组（DSHNHL）使用CEMP方案（顺铂，依托泊苷，米托蒽醌）治疗顽固性或复发性侵袭性非霍奇金淋巴瘤的老年患者的多中心随机试验结果和泼尼松）。
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkins lymphoma [O] . A Younes, J M Vose, A D Zelenetz, 2010

机译：Mapatumumab在复发/难治性非霍奇金淋巴瘤患者中进行的1b / 2期临床试验
7. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma [O] . Younes, A, Vose, J M, Zelenetz, A D, 2010

机译：Mapatumumab在复发/难治性非霍奇金淋巴瘤患者中进行的1b / 2期临床试验

A Phase 1b|[sol]|2 trial of mapatumumab in patients with relapsed|[sol]|refractory non-Hodgkin's lymphoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅